Autism Spectrum Disorder Trial, Recruiting NCT05492032 Sponsor: The Hong Kong Polytechnic University Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Autism Spectrum Disorder Trial, Recruiting

NCT05492032
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been formally diagnosed with Autism Spectrum Disorder (ASD) by a clinical psychologist, using recognised diagnostic guidelines and a structured interview process with their parents or main caregivers about their developmental history.
  • People with ASD who also have ADHD symptoms may be eligible, provided they are willing to stop taking their ADHD medications for at least 96 hours before the treatment starts and throughout the entire treatment period.
  • People with ASD who are currently taking antipsychotic medications may be eligible, provided the dose of that medication has stayed the same for six months or more before the study begins.

Who may not be able to join:

  • People who do not have a formal ASD diagnosis from a clinical psychologist, or who have a history of other neurological or psychiatric conditions, or who have had a head injury, or who are currently taking psychiatric medications.
  • People with ASD who also have epilepsy, as the treatment used in this trial (called tDCS) carries a possibility of triggering seizures.
  • People who also have a mood disorder or an anxiety disorder.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yvonne Han, PhD, The Hong Kong Polytechnic University

Phone: +852 2766 7578

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
The Hong Kong Polytechnic University
Registry
ClinicalTrials.gov
Start date
2 June 2022
Est. completion
30 September 2026

Where this trial is recruiting

Hong Kong

Primary endpoints

Change in social responsiveness - Social Responsiveness Scale-2nd edition (SRS-2)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov